Simplify Logo

Full-Time

Senior Scientist

Molecular Bioanalytics

Confirmed live in the last 24 hours

Editas Medicine

Editas Medicine

201-500 employees

Develops gene editing treatments using CRISPR

Biotechnology
Healthcare

Mid, Senior

Cambridge, MA, USA

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Requirements
  • PhD in pharmaceutics, medicinal chemistry, analytical chemistry, DMPK or a relevant discipline, with a minimum of 3 years of drug discovery experience; Bachelor’s/Master’s degrees with extensive and relevant industry experience will also be considered.
  • Extensive knowledge and experience in conducting quantitative bioanalysis using molecular bioanalytical techniques such as qPCR, ddPCR to support discovery and development projects.
  • Demonstrated knowledge and experience in establishing bioanalytical methods, ADME, PK/PD for a variety of therapeutic modalities, ideally in preclinical environment.
  • Experience in leading and developing strong, technical, delivery-focused teams is a plus.
  • Experience with gene editing or gene delivery technologies and lipid nanoparticle delivery is highly desired.
  • Excellent communication skills and proven ability to collaborate with interdisciplinary teams, along with exceptional scientific thinking and problem-solving skills.
  • Ability to multi-task to meet research and development goals in a fast-paced environment.
Responsibilities
  • Establishing and executing on routine workflows for method development using techniques such as molecular bioanalytical assays (qPCR, ddPCR) to support quantitative bioanalysis and apply innovative solutions to solve complex problems to advance the pipeline.
  • Develop and execute PCR-based methods, sample analysis, data generation, and report writing for preclinical and clinical samples.
  • Develop nucleic acid extraction (DNA/RNA) and quantification from a broad-spectrum animal tissues.
  • Responsible for the design and execution of in vitro and in vivo studies to address ADME questions aligned with our overall scientific strategy.
  • Execute bioanalytical assay development strategies to characterize ADME, PK and biodistribution properties of the drug product and address key scientific questions.
  • Ensure that the data obtained is of the highest quality, and stage appropriate.
  • Write bioanalytical assay protocols and reports that are suitable for inclusion in registration dossiers.
  • Contribute effectively to patents, reports, and publications of scientific findings.
  • Model behaviors of a strong leader and mentor to staff members as appropriate.
  • Establish strong partnerships across sites and across functions; Work cross-functionally within the R&D organization.
  • Ensure compliance with electronic notebooks (ELN), high data integrity and company policies.

Editas Medicine focuses on gene editing using CRISPR technology, which allows for precise modifications to DNA in cells. This technique has the potential to correct genetic defects that lead to various diseases. The company is engaged in the entire process of drug development, from discovering new treatments to manufacturing and bringing them to market. Editas Medicine aims to create long-lasting therapies that can greatly enhance the quality of life for patients suffering from serious illnesses. Unlike many competitors, Editas has a diverse pipeline of experimental medicines and actively shares clinical data to keep stakeholders informed. The ultimate goal is to provide effective treatments for patients worldwide, while also generating revenue through partnerships and commercialization of their genomic medicines.

Company Stage

IPO

Total Funding

$884.6M

Headquarters

Cambridge, Massachusetts

Founded

2013

Growth & Insights
Headcount

6 month growth

14%

1 year growth

22%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful clinical trials, like the EDIT-101 for Leber Congenital Amaurosis, demonstrate the potential for groundbreaking treatments.
  • The extension of collaborations with major pharmaceutical companies like Bristol Myers Squibb indicates strong industry validation and potential for future growth.
  • Recent investments, such as the $23.36 million from Marshall Wace LLP, reflect confidence in the company's innovative approach and financial stability.

What critics are saying

  • The highly competitive field of gene editing requires continuous innovation to maintain a leading position.
  • Regulatory hurdles and ethical concerns surrounding gene editing could delay or impede the commercialization of treatments.

What makes Editas Medicine unique

  • Editas Medicine leverages CRISPR technology to develop transformative treatments for serious diseases, setting it apart from traditional biotech firms.
  • The company's comprehensive approach, from discovery to commercialization, ensures a streamlined process for bringing genomic medicines to market.
  • Editas Medicine's strategic partnerships, such as with Bristol Myers Squibb, enhance its capabilities in developing gene-edited therapies.